

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>5</sup> : A61K 37/02, C07K 7/08, 7/10	A1	(11) International Publication Number: <b>WO 94/07523</b> (43) International Publication Date: 14 April 1994 (14.04.94)
<p>(21) International Application Number: PCT/US93/09414</p> <p>(22) International Filing Date: 1 October 1993 (01.10.93)</p> <p>(30) Priority data: 07/956,848      2 October 1992 (02.10.92)      US</p> <p>(71) Applicants: EMORY UNIVERSITY [US/US]; 1462 Clifton Road, N.E., Atlanta, GA 30322 (US). UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. [US/US]; Boyd Graduate Studies Research Center, DW Brooks Drive, Athens, GA 30602 (US).</p> <p>(72) Inventors: SHAFER, William ; 4550 Thicket Trail, Lithonia, GA 30058 (US). POHL, Jan ; 4093 Gladney Drive, Doraville, GA 30340 (US).</p>		<p>(74) Agents: GREENLEE, Lorraine, L. et al.; Greenlee and Winner, 5370 Manhattan Circle, Suite 201, Boulder, CO 80303 (US).</p> <p>(81) Designated States: CA, JP, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).</p> <p>Published With international search report.</p>
<p>(54) Title: ANTIMICROBIAL PEPTIDES</p> <p>(57) Abstract</p> <p>Peptides which exhibit antimicrobial activity comparable to certain known antibiotics are provided. These peptides are related in sequence to amino acid sequences within Cathepsin G. A broad spectrum bactericidal peptide disclosed herein is RPGTLCTVAGWGRVSMRRGT (SEQ ID NO:4); it is active against <i>Pseudomonas aeruginosa</i>, <i>Neisseria gonorrhoeae</i> and <i>Staphylococcus aureus</i>. RRENTQQHITARRAIRHPQY (SEQ ID NO:7) and GKSSGVPPEVFTRFVSSFLPWIRTTMR (SEQ ID NO:8) also exhibited potent activity against <i>P. aeruginosa</i> strains, including clinical isolates. The peptides of the present invention will be useful in pharmaceutical compositions useful in the treatment or prophylaxis of infections.</p>		

*FOR THE PURPOSES OF INFORMATION ONLY*

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NE	Niger
BE	Belgium	GN	Guinea	NL	Netherlands
BF	Burkina Faso	GR	Greece	NO	Norway
BG	Bulgaria	HU	Hungary	NZ	New Zealand
BJ	Benin	IE	Ireland	PL	Poland
BR	Brazil	IT	Italy	PT	Portugal
BY	Belarus	JP	Japan	RO	Romania
CA	Canada	KP	Democratic People's Republic of Korea	RU	Russian Federation
CF	Central African Republic	KR	Republic of Korea	SD	Sudan
CG	Congo	KZ	Kazakhstan	SE	Sweden
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovak Republic
CM	Cameroon	LU	Luxembourg	SN	Senegal
CN	China	LV	Latvia	TD	Chad
CS	Czechoslovakia	MC	Monaco	TG	Togo
CZ	Czech Republic	MG	Madagascar	UA	Ukraine
DE	Germany	ML	Mali	US	United States of America
DK	Denmark	MN	Mongolia	UZ	Uzbekistan
ES	Spain			VN	Viet Nam
FI	Finland				

## ANTIMICROBIAL PEPTIDES

5 This invention was made, in part, with funding from the National Institutes of Health and from the Department of Veterans Affairs Research Service. The United States Government may have certain rights in this invention.

Technical Field

10 The field of this invention is the area of antimicrobial peptides with activity against a broad range of Gram negative and Gram positive bacteria and fungi. The antimicrobial peptides of this invention are useful for inhibiting microbial growth and in pharmaceutical compositions for treatment or prevention of infections and for the treatment and/or  
15 prevention of gingivitis.

Background of the Invention

Microbes which invade the human body are challenged by several defense mechanisms. The nature of the defense mechanisms which any given microbe faces depends on the  
20 genetic makeup and the physiologic state of the host as well as the portal of entry of the invading microorganism.

If the mechanical and chemical barriers of the skin or mucous membranes are crossed, immunological factors (e.g.,

nonspecific cellular defenses come into play. Nonspecific cellular defenses in the form of phagocytic white blood cells from local tissues and the bloodstream respond to an invading microbe. Polymorphonuclear leukocytes (PMNs) actively phagocytize particulates such as bacterial or fungal cells. PMNs are the first class of phagocytic cells recruited to the site of infection or inflammation. The PMNs contain azurophilic or primary granules, which contain lysosomal proteases, myeloperoxidase, lysozyme and certain antimicrobial proteins. Secondary granules within these cells contain alkaline phosphatase, lactoferrin and lysozyme. Stores of glycogen within the PMNs provides for energy through glycolysis so that the cell can function in an anaerobic environment.

Adherence of a particle to the surface of a phagocytic cell initiates phagocytosis; the particle enters the cytoplasm in a phagocytic vacuole. This triggers a respiratory burst and the generation of microbicidal metabolites; the primary granule fuses with the phagocytic vacuole to form a digestive vacuole called the phagolysosome. Intracellular killing of the ingested microorganism occurs as a result of oxygen-dependent and oxygen-independent mechanisms. The oxygen-dependent bactericidal halogenating system uses, for example, granule myeloperoxidase, hydrogen peroxide and chloride ion to kill bacteria and viruses via either halogenation of cellular or viral constituents or via reactive oxygen intermediates.

The primary granules contain three major groups of antibacterial proteins. The first group includes catalytically active proteins which are only weakly antibacterial when tested individually in purified form; examples include lysozyme, elastase and collagenase. These enzymes probably participate in the digestion of microorganisms killed by other mechanisms, but elastase, for example, is believed to potentiate killing by the halogenating system. The second category of granule proteins includes

those with catalytic activity and bactericidal activity which is independent of the catalytic activity. An example is the chymotrypsin-like neutral protease of human neutrophils. The third group contains bactericidal members which lack known catalytic activity; included in this class are defensins and cationic antibacterial proteins.

Some cationic antibacterial proteins are of relatively high molecular weight (greater than about 25 kDa) and kill certain Gram negative bacteria, such as Escherichia coli, Salmonella typhimurium and Pseudomonas aeruginosa, by damaging the cytoplasmic membrane, leading to increased membrane permeability. Human bactericidal/permeability increasing protein (BPI) is a strongly basic protein with molecular weight of about 59 kDa. It is believed that binding of BPI to the outer membrane of susceptible bacterial cells results in exposure of hydrophobic channels through the outer envelope, and as a secondary effect, a selective activation of autolytic enzymes. Gram positive bacteria, certain Gram negative bacteria and fungi are not affected by BPI in vitro.

Low molecular weight cationic proteins (10 kDa to 25 kDa) have been reported to inhibit the multiplication of such Gram positive bacteria as Staphylococcus aureus (Root and Cohen (1981) Rev. Infect. Dis. 3:565-598). In addition, cationic proteins with fungicidal activity have been identified in alveolar macrophages. It is believed that cationic proteins are most efficient in killing phagocytized microorganisms in combination with other microbicidal defense mechanisms (Elsbach and Weiss (1983) supra).

Generally defensins are relatively small polypeptides (3-4 kDa), which are rich in cysteine and arginine. Gabay et al. (1989) Proc. Natl. Acad. Sci. USA 86:5610-5614, used reverse phase HPLC to purify 12 major polypeptides from the azurophil granules of human PMNs; purified proteins were analyzed individually for antimicrobial activity and for N-terminal

amino acid sequence. A 4 kDa defensin (HNP-4) and a 29 kDa polypeptide named azurocidin were purified and shown to possess broad spectrum antimicrobial activity. Defensins as a class have activity against some bacteria, fungi and viruses. They are also reported to have cytotoxic activity against transformed cells. Selsted et al. (1985) J. Clin. Invest. 76:1436-1439, presents a sequence comparison of human and rabbit defensins. The defensins are believed to have molecular conformations stabilized by cystine infrastructure, which are essential for biological activity.

Granzymes are a family of serine proteases in the granules of cytolytic lymphocytes. Proteolytic enzymes are believed to function in cell-mediated cytotoxicity; some of the genes have been cloned, and sequence information is available. Within the granzyme family there is at least 38% amino acid sequence identity. Human lymphocyte protease has 73% amino acid sequence identity to mouse granzyme B (Jenne and Tschopp (1988) Immunol. Reviews 103:53-71).

Another class of antimicrobial polypeptides are those known as magainins; at least five proteins can be isolated from the skin of the African clawed frog (Xenopus laevis). The natural proteins are active against a broad range of microorganisms including bacteria, fungi and protozoans (Zasloff (1987) Proc. Natl. Acad. Sci. USA 84:5449-5453). This antimicrobial activity is also present in synthetic peptides and certain truncated analogs of the natural proteins. Derivatives of about 19 to about 23 amino acids have antibacterial activity as measured using Escherichia coli. In the protozoan Paramecium caudatum treated with the magainin peptides, there is disruption of membrane functions. The configurations of the bioactive peptides can be modeled as amphiphilic alpha-helices and are sufficiently long to span a lipid bilayer. (Zasloff et al. (1988) Proc. Natl. Acad. Sci. USA 85:910-913). The sequence of a representative magainin

peptide is GIGKFLHSAKKFKAFVGEIMN (Zasloff et al. (1988) supra) (SEQ ID NO:1).

5           Cathepsin G (Cat G) is a granule protein with  
chymotrypsin-like activity; it is also known as chymotrypsin-  
like cationic protein. Cat G (Odeberg and Olsson (1975) J.  
Clin. Invest. 56:1118-1124) and three other mutually  
homologous polypeptides called defensins are active against a  
broad spectrum of gram positive bacteria, Gram negative  
bacteria and fungi (Shafer et al. (1986) Infect. Immun.  
10   54:184-188; Shafer et al. (1988) Infect. Immun. 56:51-53;  
Drazin and Lehrer (1977) Infect. Immun. 17:382-388; Ganz et  
al. (1986) Semin. Respir. Infect. 1:107-117). Sensitive  
bacteria include Capnocytophaga sputigena, Escherichia coli,  
Listeria monocytogenes, Neisseria gonorrhoeae, Pseudomonas  
15   aeruginosa and S. aureus. All of these pathogens, with the  
notable exceptions of P. aeruginosa and C. sputigena, are only  
sensitive to both enzymatically-active and -inactive cathepsin  
G (Miyasaki and Bodeau (1991) J. Clin. Invest 87:1585-1593;  
Wasiluk et al. (1991) Infect. Immun. 59:4193-4200 and Table  
20   8). P. aeruginosa and C. sputigena are only sensitive to  
enzymatically-active cathepsin G. It is not clear, however,  
if cathepsin G-killing of these two pathogens requires  
degradation of bacterial proteins or whether an intact active  
site is needed to align antibacterial domains of cathepsin G  
25   with the bacterial target.

          Gabay et al. (1989) supra, has reported antibacterial  
activities of a number of proteins isolated from human PMNs,  
including cathepsin G and elastase, and has given the amino  
terminal sequence of these and other proteins. The N-terminal  
30   five amino acids of elastase and Cat G are identical; further  
sequences have significant relatedness. The amino acid  
sequence of human Cat G is known, (Salvesen et al. (1987)  
Biochemistry 26:2289-2293). Sequence analysis of the cDNA  
revealed significant sequence identity to rat mast cell

proteinase (47%) and to an activated mouse cytotoxic lymphocyte product (56%).

Cat G also exhibits significant sequence similarity to chymotrypsin, which is not known to exhibit antimicrobial activity similar to that of Cat G.

As described in WO 91/04414, the Cat G protein was analyzed to determine whether the same portions of the protein were responsible for the enzymatic and antibacterial activity. Purified human Cat G was digested with the proteolytic enzyme clostripain. Peptides resulting from that digestion were purified and individually tested for antibacterial and enzymatic activity. None of the peptides tested exhibited the chymotrypsin-like activity of the intact molecule. However, two Cat G-derived peptides exhibited antibacterial activity using Staphylococcus aureus or Neisseria gonorrhoeae as the indicator organism. Those peptides were IIGGR (SEQ ID NO:2; amino acids 1-5) and HPQYNQR (SEQ ID NO:3; amino acids 77-83). Antimicrobial activity was maintained with some variation in amino acid sequence, as described in WO 91/04414. Similarly, the oligopeptide corresponding in amino acid sequence to amino acids 1-20 of Cat G exhibited strong bactericidal activity against Pseudomonas aeruginosa.

#### Summary of the Invention

It is an object of this invention to provide oligopeptides with antimicrobial activity. The antimicrobial oligopeptides of the present invention contain from five to about twenty-six amino acids joined in a linear array by peptide bonds, preferably from ten to about twenty-six amino acids.

An object of the present invention is a broad spectrum bactericidal oligopeptide, termed CG 117-136 herein, which has the sequence RPGTLCTVAGWGRVSMRRGT (SEQ ID NO:4). The present invention includes the CG 117-136 oligopeptide in which all

correspondent amino acids are L-amino acids (L-enantiomer) and the CG 117-136 peptide in which all the component amino acids are D-amino acids (D-enantiomer). Further objects are additional bactericidal oligopeptides, particularly effective for P. aeruginosa but not for S. aureus or N. gonorrhoeae, which oligopeptides are termed CG 122-136, CG 127-136, CG 61-80 and CG 198-223, herein. CG 122-136 has the amino acid sequence CTVAGWRGVSMRRGT (SEQ ID NO:5) and CG 127-136 has the amino acid sequence WGRVSMRRGT (SEQ ID NO:6). CG 61-80 has the amino acid sequence RRENTQQHITARRAIRHPQY (SEQ ID NO:7) and CG 196-223 has the sequence GKSSGVPPEVFTFRVSSFLPWIRTMR (SEQ ID NO:8).

In other embodiments, the antimicrobial oligopeptides comprise the amino acid sequence of CG 1-20, i.e. IIGGRESRPHSRPYMAYLQI (SEQ ID NO:9). CG 1-20 has antimicrobial activity against bacteria including, but not limited to, Pseudomonas aeruginosa and oral pathogens such as Capnocytophaga sputigena, Eikenella corrodens and Actinobacillus actinomycetemcomitans.

D-enantiomers of the antimicrobial oligopeptides of the present invention are particularly preferred.

An object of the present invention is to provide antimicrobial oligopeptides which are useful as bactericides and/or bacteriostats, useful, for example, for killing microorganisms or for inhibiting microbial growth in a variety of solutions and sterile solutions, such as contact lens solutions, herbicidal solutions, hazardous or refuse waste streams, surface disinfectant solutions and oil recovery fluids.

A further object of the invention is to provide therapeutic compositions, suitable for human, veterinary, agricultural or pharmaceutical use, comprising one or more of the antimicrobial oligopeptides of the present invention and a

suitable pharmacological carrier. Such therapeutic compositions can be formulated as understood in the art, e.g., for topical or aerosol application, for controlling and/or preventing infection by Gram positive or Gram negative bacteria or fungi. Preferably, the antimicrobial oligopeptides of the present invention are used in the treatment of infections by Gram negative or Gram positive bacteria. The antimicrobial oligopeptides of the present invention, when used in therapeutic compositions, will not have significant immunogenic activity. In vitro antimicrobial activity of the oligopeptides of the present invention is an accurate predictor of in vivo antimicrobial activity.

Pharmaceutical compositions contain a therapeutically effective amount of an antimicrobial oligopeptide. A therapeutically effective amount of an antimicrobial oligopeptide can be readily determined according to methods known in the art. Pharmaceutical compositions are formulated to contain the therapeutically effective amount of an antimicrobial oligopeptide and a pharmaceutically acceptable carrier appropriate for the route of administration (topical, gingival, intravenous, aerosol, local injection) as known to the art. For agricultural use, the composition comprises a therapeutically effective amount of an antimicrobial oligopeptide and an agriculturally acceptable carrier suitable for the organism (e.g., plant) to be treated. Preferably for use in a pharmaceutical composition, the antimicrobial oligopeptide will have an  $ED_{50}$  in vitro less than about  $10^{-3}$  M. The skilled artisan can readily determine a therapeutically effective amount against a target bacterial strain, for example, based on the  $ED_{50}$  using the methods disclosed herein and the teachings of the art.

Therapeutic compositions may be administered by topical, dental rinse, aerosol or intravenous application, or by local injection for the control or prevention of infection, by any means known to the art.

IIGGRESRPHSRPYMAYLQI (SEQ ID NO:9) may also be used to kill or control the growth of tumor cells or virus-infected cells. In such applications, these peptides will be particularly useful when coupled to antibodies or other molecules which are specific for the target tumor cell or virus-infected cell so that the peptide acts specifically on the tumor or virus-infected cell.

#### Brief Description of the Figures

Figure 1 illustrates the complete amino acid sequence for the mature human cathepsin G, as deduced from analysis of its cDNA (See also SEQ ID NO:10). In the chymotrypsin nomenclature, it displays the charge relay profile of His57 Asp102 Ser195 that is typical of serine proteases; the charge relay system amino acids are identified with an asterisk (\*). The Ser195 residue (residue 181 in the mature cathepsin G protein) is the target of phosphorylation by DFP, resulting in irreversible inhibition of chymotryptic activity. The residues lining the primary specificity pocket of cathepsin G are marked with #.

Figure 2 presents hydrophobicity analysis for peptide CG 117-136 (SEQ ID NO:4) and the corresponding hydrophobicity-hydrophilicity plot for the amino acid sequence.

#### Detailed Description of the Invention

As used herein, an oligopeptide is composed of from about five to about twenty-six amino acids linked together by peptide bonds in a linear array. The peptide may be in a linear conformation or it may assume secondary structure. A cyclic peptide derivative can also have antimicrobial activity, and thus is a functional equivalent of the antimicrobial peptides of the present invention. Sequences are conventionally given from the amino terminus to the carboxyl terminus. Component amino acids may be of the D- or

the L-configuration. Unless otherwise noted, the amino acids are L-amino acids. When all component amino acids are of L-configuration, the peptide is said to be an L-enantiomer. When all the amino acids in a peptide are in the D-configuration, that peptide is said to be a D-enantiomer. The peptides of the present invention have antimicrobial activity by themselves or when coupled to another molecule, e.g., polyethylene glycol or a carrier protein such as bovine serum albumin, so long as the peptides are positioned such that they can come into effective contact with the target cell.

Table 1 presents most abbreviations used in this application. Other abbreviations are as commonly used in the art.

TABLE 1  
Abbreviations

A	= Ala = Alanine	M	= Met = Methionine
C	= Cys = Cysteine	N	= Asn = Asparagine
D	= Asp = Aspartic Acid	P	= Pro = Proline
E	= Glu = Glutamic Acid	Q	= Gln = Glutamine
F	= Phe = Phenylalanine	R	= Arg = Arginine
G	= Gly = Glycine	S	= Ser = Serine
H	= His = Histidine	T	= Thr = Threonine
I	= Ile = Isoleucine	V	= Val = Valine
K	= Lys = Lysine	W	= Try = Tryptophan
L	= Leu = Leucine	Y	= Tyr = Tyrosine
Boc	= <u>tert</u> -butyloxycarbonyl		
CFU	= colony forming unit		
DFP	= diisopropylfluorophosphate		
HLE	= human leukocyte elastase		
Pam	= (phenylacetamido) methyl		

ED<sub>50</sub> is the concentration of an antimicrobial agent which kills (or otherwise inhibits growth) 50% of the input indicator microorganisms or cells under particular test conditions.

5 For convenience, the peptides disclosed herein are named according to the amino acid positions in mature Cat G (Fig. 8).

10 CG 1-20 represents amino acid residues 1-20 of the mature Cat G sequence and has the sequence IIGGRESRPHSRPYMAYLQI (SEQ ID NO:9).

CG 21-40 corresponds in sequence to amino acids 21-40 of Cat G, QSPAGQSRCGGFLVREDFVL (SEQ ID NO:11).

CG 41-60, corresponding to amino acids 41-60 of Cat G, has the sequence TAAHCWGSNINVTLGAHNIQ (SEQ ID NO:12).

15 CG 61-80, corresponding to amino acids 61-80 of Cat G, has the sequence RRENTQQHITARRAIRHPQY (SEQ ID NO:7).

CG 77-96, corresponding to amino acids 77-96 of Cat G, has the amino acid sequence HPQYNQRTIQNDIMLLQLSR (SEQ ID NO:13).

20 CG 97-116, corresponding to amino acids 97-116 of Cat G, has the sequence RVRNRNRVNPVALPRAQEG (SEQ ID NO:14).

CG 117-136, corresponding to amino acids 117-136 of Cat G, has the sequence RPGTLCTVAGWGRVSMRRGT (SEQ ID NO:4).

25 CG 137-156, corresponding to amino acids 137-156 of Cat G, has the sequence DTLREVQLRVQRDRQCLRIF (SEQ ID NO:15).

CG 157-176, corresponding to amino acids 157-176 of Cat G, has the sequence GSYDPRRQICVGDRRERKAA (SEQ ID NO:16).

CG 177-197, corresponding to amino acids 177-197 of Cat G, has the sequence FKGDSSGGPLLCNNVAHGIVSY (SEQ ID NO:17).

CT 198-223, corresponding to amino acids 198-223 of Cat G, has the sequence GKSSGVPPEVFTRFVSSFLPWIRTTMR (SEQ ID NO:8).

Antimicrobial activity, as used herein, refers to the ability of a peptide of the present invention to kill at least one species selected from the group consisting of Gram positive bacteria, Gram negative bacteria, fungi, and protozoans. It is increasingly preferred that the peptide kill at least 50%, 60%, 70%, 80%, 90% or all cells of at least one species of Gram positive or Gram negative bacteria, fungi, or protozoans. Sensitive Gram positive bacteria can include, but are not limited to, Staphylococcus aureus. Sensitive Gram negative bacteria include, but are not limited to, Escherichia coli, Neisseria gonorrhoeae, and Pseudomonas aeruginosa. Periodontal disease-associated bacteria include Capnocytophaga sputigena, Actinobacillus actinomycetemcomitans and Eikenella corrodens. Capnocytophaga sputigena ATCC 33123 is sensitive to IIGGR (SEQ ID NO:2), IIGGRESRPHSRPYMAYLQI (SEQ ID NO:9) and HPQYNQR (SEQ ID NO:3). A. actinomycetemcomitans is sensitive to IIGGR and HPQYNQR. E. corrodens is more sensitive to IIGGR than to HPQYNQR. Sensitive fungi can include, but are not limited to, Candida albicans. Antimicrobial activity can also refer to the ability to kill or inhibit the growth of other cells, in particular, those which are tumor cells or virus-infected cells.

The antimicrobial peptides of the present invention are oligopeptides which possess antimicrobial activity, as defined herein. These antimicrobial peptides may contain modifications such as acetylation, provided that the antimicrobial activity is not destroyed. Chemical modifications which do not destroy antimicrobial activity are those which do not substantially decrease the hydrophilicity of the antimicrobial peptide and those which are not bulky

hydrophobic chemical groups, particularly as described in WO 91/04414 for antimicrobial peptides related in sequence to HPQYNQR. Modified peptides with antimicrobial activity are functionally equivalent to the antimicrobial peptides of the present invention. Such modified peptides with antimicrobial activity include, but are not limited to, (1-methyl-H)QYNQR, (3-methyl-H)PQYNQR, (Ac-H)PQYNQR and HPAYNA<sup>M</sup>K.

Antibacterial pharmaceutical compositions, as defined herein, comprise a pharmaceutically acceptable carrier and one or more antibacterial peptides of the present invention. Such antimicrobial pharmaceutical compositions may be formulated in ways, as understood in the art, for use for topical application, for gingival application (for gingivitis or periodontal disease) or for local or systemic injection. For use in the treatment or prevention of gingivitis, the peptides of the present invention can be incorporated in effective amounts in a dental rinse for application to the buccal area, or they may be incorporated in other suitable compositions for topical application. The antibacterial peptides of the present invention may also be incorporated in effective amounts in chewing gum, lozenges for sucking, toothpowder or toothpaste. The antibacterial peptides of the present invention can comprise from 0.001% to 50% by weight of such compositions. It will be understood that a composition for systemic injection will contain an antimicrobial peptide, e.g., an antibacterial peptide such as CG 117-136, in a therapeutically effective amount or a therapeutically effective amount of an antimicrobial peptide can be conjugated to an antibody, or any other compound as understood in the art, with specificity for the target cell type. The choice of the peptide will be made with consideration of immunogenicity and toxicity to the infected host, effective dose of the peptide, and the sensitivity of the target microbe to the peptide, as well-understood in the art.

Surprisingly, an oligopeptide of the sequence HPQYNQRTIQNDIMLLQLSR (SEQ ID NO:13) did not exhibit significant antimicrobial activity against either S. aureus or P. aeruginosa, although peptides of the sequences HPQYNQ (SEQ ID NO:18) and HPQYNQR (SEQ ID NO:3) were bactericidal.

Cat G-derived peptides were tested for antimicrobial activity against Capnocytophaga sputigena ATCC 33123, which is the same as that now available as C. sputigena ATCC 33612 (American Type Culture Collection, Rockville, Maryland). C. sputigena is representative of oral pathogens associated with periodontal disease and/or gingivitis. IIGGR (SEQ ID NO:2) and CG 77-83 (SEQ ID NO:3) are effective against C. sputigena ATCC 33123 in vitro. When incorporated in pharmaceutical compositions, one or more of the peptides related in sequence to Cat G can be used to ameliorate gingivitis and/or treat periodontal disease. Compositions for oral use include oral rinses, lozenges and formulations for topical application to the gums. The skilled artisan can use the teachings of the present specification and knowledge readily accessible to the art to prepare pharmaceutically useful formulations for oral application, topical or other applications, particularly after animal studies to confirm that these peptides are not toxic to the human or animal host and are effective in vivo.

Because the antimicrobial activity resulting from the IIGGR (SEQ ID NO:2) and HPQYNQR (SEQ ID NO:3) peptides (recovered after clostripain digestion as described in WO 91/04414) was less than 1% of the activity of intact Cat G, an alternate approach was pursued. Eleven peptides spanning the entire 223 amino acid cathepsin G protein were synthesized. These eleven peptides were tested for antibacterial action against N. gonorrhoeae, P. aeruginosa and S. aureus. Of the eleven peptides, only the peptide corresponding to residues 117-136 in the full-length cathepsin G (CG 117-136) (SEQ ID NO:4) displayed antibacterial action against all three pathogens; 500  $\mu$ g of peptide per ml killed 5-6 logs of P.

aeruginosa and S. aureus. See Table 6 for the peptide sequences and activities, as measured using a crude peptide concentration of 500  $\mu\text{g/ml}$  with an input viable cell concentration of about  $10^7$  colony forming units/ml (CFU/ml) in 1/100 strength HBSS. CG 117-136 will be useful as an antibacterial agent against a wide range of bacteria, including pathogens.

5

Table 2  
Antibactericidal Activity of Crude Peptides<sup>1</sup>

5	Peptide Sequence	Log Kill (500 µg/ml)	
		<u>P. aeruginosa</u> ATCC 27853	<u>N. gonorrhoeae</u> strain WS1
	CG 1-20 (SEQ ID NO:9)	<b>5.507</b>	<b>2.57</b>
10	CG 21-40 (SEQ ID NO:11)	-0.034	0.05
	CG 41-60 (SEQ ID NO:12)	0.5	-0.09
15	CG 61-80 (SEQ ID NO:7)	<b>5.15</b>	0
	CG 77-96 (SEQ ID NO:13)	0.06	0.24
	CG 97-116 (SEQ ID NO:14)	<b>5.93</b>	-0.21
20	CG 117-136 (SEQ ID NO:4)	<b>5.88</b>	<b>2.38</b>
	CG 137-156 (SEQ ID NO:15)	0.01	0.43
25	CG 157-176 (SEQ ID NO:16)	1.02	-0.18
	CG 177-197 (SEQ ID NO:17)	-0.79	0.68
	CG 198-223 (SEQ ID NO:8)	<b>5.73</b>	0.78
30	Buffer	-0.139	-0.07

<sup>1</sup> Peptides shown in **Bold** were purified by RP-HPLC and again tested vs. P. aeruginosa, N. gonorrhoeae and S. aureus (see Table 3A).

Table 3A provides antimicrobial activities of peptides purified by RP-HPLC, determined as above. Only CG 117-136 (SEQ ID NO:4) exhibits high activity against P. aeruginosa, S. aureus and N. gonorrhoeae. Table 3B discloses the ED<sub>90</sub> in  $\mu\text{g/ml}$  for the antibacterial peptides, as measured with P. aeruginosa ATCC 27853 as above. ED<sub>90</sub> is the dose required to kill 90% of the input cells in 2 h at 37°C in 1/100 strength HBSS, where the input viable cell concentration is about  $10^7$  CFU/ml.

Even more effective as an antimicrobial agent than amino acids 1-5 of Cat G is the CG 1-20 oligopeptide (SEQ ID NO:9) but which retains some blocking group(s) from the component derivatized amino acids in chemical peptide synthesis or an artifactual reaction product. The chemical identity of the substituents on that oligopeptide or reaction product have not yet been identified. CG 97-116 (SEQ ID NO:14) also exhibits strong antimicrobial activity as a crude synthetic product, but is not as a purified peptide. The basis for this is also not defined.

Table 3A  
Antibacterial Action of RP-HPLC-Purified Peptides

5	Peptide 8325-4	SEQ ID NO.	Log Kill (500 µg/ml)		
			<i>P. aeruginosa</i> ATCC 278533	<i>N. gonorrhoeae</i> strain WSI	<i>S. aureus</i> strain
10	CG 1-20	9	1.0	0.43	0.3
	CG 61-80	7	5.15 <sup>1</sup>	ND <sup>2</sup>	0.58
	CG 97-116	14	0.22	0.2	-0.1
	CG 117-136	4	5.88 <sup>1</sup>	4.20	5.34
	CG 198-223	8	5.73 <sup>1</sup>	ND	0.26
15	Buffer Control		-0.139	-0.07	-0.25

<sup>1</sup> Also active against four clinical isolates of *P. aeruginosa*

<sup>2</sup> Not determined

Table 3B  
20 Potency of Synthetic Cathepsin G Peptides Against *P. aeruginosa*

25	Synthetic Peptides	SEQ ID NO.	ED <sub>90</sub> (µg/ml)
	CG 1-20	9	500
	CG 61-80	7	75
	CG 97-116	14	>500
	CG 117-136	4	15
	CG 198-223	8	115

It was noted that CG 1-20 (SEQ ID NO:9) and CG 97-116 (SEQ ID NO:14) were highly active as crude peptides, but exhibited much lower activity when purified by RP-HPLC. Without wishing to be bound by any particular hypothesis, the inventors suggest that the high activity in the crude peptide preparation is due to one or more residual blocking or substituent groups or some unidentified side reaction product generated during the hydrogen fluoride cleavage and/or post-synthetic work-up.

Those peptides which exhibited significant activity against P. aeruginosa ATCC 27853, were also tested against four independent clinical isolates. P. aeruginosa ATCC 27853 (American Type Culture Collection, Rockville, Maryland) is the strain used for testing antimicrobial activity against P. aeruginosa unless otherwise noted. It is a standardized strain for antibiotic-susceptibility testing of pseudomonads (see, e.g., Code of Federal Regulations, Title 21, Part 460, 1987). CG 61-80 (SEQ ID NO:7) and CG 198-223 (SEQ ID NO:8) exhibited some variability in effectiveness for killing of clinical strains, but so far as tested, CG 117-136 (SEQ ID NO:4) appeared to be a highly effective bactericidal peptide for P. aeruginosa as well as N. gonorrhoeae and S. aureus (see Tables 3A, 4). Agents effective against P. aeruginosa are needed in the art because multiple antibiotic resistance is quite common among clinical strains, and therefore resultant infections are often difficult to treat.

Table 4  
Bactericidal Activity of HPLC-Purified Peptides  
Against P. aeruginosa Clinical Isolates

5	Log Reduction in Viability <sup>1</sup>				
	<u>P. aeruginosa</u> 223 NO:8)	Control	CG 61-80 (SEQ ID NO:7)	CG 117-136 (SEQ ID NO:4)	CG 198- 223 (SEQ ID
10					
	ATCC 27853	-0.14	5.49	5.95	5.35
	#385128	-1.1	1.91	6.17	4.71
	#36152	-0.89	4.86	5.38	4.28
	#27853	-0.58	5.80	5.79	4.80
15	#A-91-330-0347	-0.41	4.11	6.40	1.17

<sup>1</sup> 3-5 X 10<sup>7</sup> CFU/ml of the designated strains were exposed to 500 µg/ml of HPLC-purified peptides in 1/100 strength BHSS (10 mM sodium phosphate, pH 7.0, 10 mM NaCl).

20 To further characterize the activity of CG 117-136 (SEQ ID NO:4), a "D-enantiomer," composed only of D-amino acids but in the same sequence, was synthesized and tested for antimicrobial activity. The L- and D-forms of this same amino acid sequence had equivalent bactericidal activity against

25 both P. aeruginosa and N. gonorrhoeae (Table 5). This result suggests that killing does not require the recognition of a microbial target with a chiral center.

Table 5

The Antibacterial Capacity of CG 117-136 (SEQ ID NO:4)  
is Independent of Stereochemistry

5

Peptide	<u>P. aeruginosa</u>	Log Kill <sup>1</sup>
	ATCC 27853	<u>N. gonorrhoeae</u> strain WS1
L-enantiomer	5.62	4.20
D-enantiomer	5.92	4.20

10

15

<sup>1</sup> P. aeruginosa ( $3 \times 10^7$  CFU/ml) was exposed to 125  $\mu$ g/ml of each peptide, while N. gonorrhoeae ( $5 \times 10^6$  CFU/ml) was exposed to 500  $\mu$ g/ml of each peptide.

20

The D-and L-enantiomers of CG 117-136 (SEQ ID NO:4) were tested for retention of bactericidal activity in the presence of normal mouse serum (NMS). As shown in Table 6, NMS at a concentration of 25% (v/v) in 1/100 HBSS completely inhibited the microbicidal activity of the L-enantiomer. However, the D-enantiomer of CG 117-136 retained significant antimicrobial activity. Without wishing to be bound by any theory, it is suggested that NMS contains endogenous inhibitors or proteases that specifically destroy or inhibit the bactericidal activity of the L-enantiomer of CG 117-136 (SEQ ID NO:4).

25

Table 6  
Bactericidal Activity of L- and D-Enantiomers  
of CG 117-136 (SEQ ID NO:4) in the Presence of  
Normal Mouse Serum

5

Sample	Log Reduction in Viability of <u>P. aeruginosa</u>
10	Bacteria
	-0.02
	Bacteria + NMS
	-0.16
	Bacteria + L-enantiomer
	≤5.6
	Bacteria + L-enantiomer + NMS
	-0.19
	Bacteria + D-enantiomer
	≤5.6
15	Bacteria + D-enantiomer + NMS
	3.80

20

The L- and D-enantiomeric forms of CG 117-136 (SEQ ID NO:4) were tested for apparent lethality or toxicity to mice. In a pilot experiment, 6 BALB/cAnNCr mice were given an intraperitoneal injection of 500 µg of the L-enantiomeric form of CG 117-136 and 6 BALB/cAnNCr mice were given 500 µg of the D-enantiomeric form of CG 117-136 by intraperitoneal injection. All 12 test mice remained alive and active at 14 days post injection. Thus, neither the L- nor the D-enantiomer of CG 117-136 has apparent toxicity to mice.

25

30

35

As shown in Fig. 2B and Table 7A, CG 117-136 (SEQ ID NO:4) is predicted to have a hydrophobic domain in the N-terminal portion of the peptide and a cationic, hydrophilic domain in the C-terminal portion. The contribution(s) of these domains to antimicrobial activity was assessed by synthesizing truncated versions of CG 117-136. Both domains were required for full activity. Omission of either C- or N-terminal residues destroyed activity against S. aureus, while omission of the five N-terminal residues resulted in only about a 10-fold drop in activity for both P. aeruginosa and N.

gonorrhoeae. Omission of the ten N-terminal residues caused nearly total loss of activity against P. aeruginosa and a lesser reduction in activity as measured against N. gonorrhoeae (see Table 7A, 7B).

5

Table 7A  
Summary of Domains in CG 117-136 and in  
Truncated CG 117-136 Variants

Peptide	Hydrophobic Domain	Hydrophilic Domain
CG 117-136 (SEQ ID NO:4)	+	+
CG 117-129 (SEQ ID NO:19)	+	-
CG 122-136 (SEQ ID NO:5)	±	+
CG 127-136 (SEQ ID NO:6)	-	+

15

Table 7B  
Antibacterial Action of CG 117-136 and  
Truncated Variants of CG 117-136

		Log Kill (500 µg/ml)		
		<i>P. aeruginosa</i>	<i>N. gonorrhoeae</i>	<i>S. aureus</i>
Peptide	SEQ ID	ATCC 27853	strain WSI	strain
8325-4	NO.			
CG 117-136	4	5.8	4.20	5.34
CG 117-129	19	0.86	0.05	0
CG 122-136	5	4.75	4.18	0
CG 127-136	6	0.27	3.20	0

25

5 The secondary structure of CG 117-136 (SEQ ID NO:4) has been predicted by computer analysis to exhibit  $\beta$ -Sheet structure. By contrast, several peptides known to interrupt the Gram negative envelope are  $\alpha$ -helical peptides (See, e.g., Vaara, M. (1992) Microbiological Rev. 56:395-411).

10 The potent antibacterial peptide CG 117-136 (SEQ ID NO:4) displays partial amino acid sequence identities with limited portions of other serine proteases or serine protease-like proteins, termed serpocidins, based on their toxic action against bacteria and eucaryotic cells. The partial sequence identities are less than 50% over the relevant portions, but may be significant. The mechanism of cytotoxicity has not been defined, but it is likely that the serpocidins behave as membrane-disorganizing agents. Electron microscopic analysis of CG 117-136-treated P. aeruginosa cells revealed similar effects on cell morphology to those seen after treatment with polycationic agents. Lysis did not result from CG 117-136 treatment.

20 A comparison of the amino acid sequence of CG 117-136 to partial sequences of other antimicrobial proteins and serine proteases is given in Fig. 3. The dots represent amino acid identity. The skilled artisan can readily identify variants of the exemplified CG 117-136 sequence (SEQ ID NO:4) (or of other antibacterial peptides disclosed herein) by synthesizing defined variants and testing as taught herein.

30 The sensitivities of the P. aeruginosa and S. aureus indicator cells to enzymatically-active and inactive Cat G were determined (see Table 8). Surprisingly, peptides CG 61-80, CG 117-136, CG 198-223 (SEQ ID NO:7, SEQ ID NO:4, and SEQ ID NO:8, respectively) from cathepsin G display potent bactericidal action in vitro even against a pathogen (P. aeruginosa) that is killed only by enzymatically active Cat G.

Table 8

Bactericidal Capacities of Enzymatically-Active  
and -Inactive Cathepsin GLog Reduction in CFU/ml<sup>1</sup>

5

	<u>S. aureus</u>	<u>P. aeruginosa</u>
Control	-0.18	-0.76
10 50 µg/ml enzymatically active Cat G	2.82	2.41
50 µg/ml DFP-treated Cat G	2.93	0.125

15

<sup>1</sup> Approximately 5 X 10<sup>6</sup> CFU/ml of the test bacteria were incubated with the cathepsin G samples in 1% (w/v) TSB (trypticase soy broth) for 2 h at 37°C. The results are average values from 2 determinations for each strain and preparation of cathepsin G.

20

Only enzymatically-active cathepsin G kills P. aeruginosa, while other pathogens are readily killed by both active and inactive cathepsin G. It is theorized that in order for the antibacterial peptides to properly interact with the pseudomonad cell envelope, the structure of the active site must be in its native state in order to allow accessibility of bactericidal domains in the full-length molecule or promote liberation of bactericidal fragments the full-length molecule by a mechanism such as bacterial protease action or by autoproteolysis, but the inventors do not wish to be bound by this theory. The results disclosed herein support the notion

30

that bactericidal serine esterases possess broad spectrum antibacterial action due to the presence of internal antibacterial domains and that multiple, distinct domains exist within cathepsin G for the purpose of killing different pathogens.

The following examples are provided for illustrative purposes and are not intended to limit the scope of the invention. Because modification of the examples below will be apparent to those of skill in the art, it is intended that this invention be limited only by the scope of the appended claims. All references cited in this application are hereby incorporated by reference herein.

#### EXAMPLES

##### Example 1 Preparation of Synthetic Peptides

Oligopeptides were synthesized using an Applied Biosystems Model 430A peptide synthesizer (0.1 - 0.5 mmol scale) using phenylacetamidomethyl (Pam) or p-methylbenzyhydramine copoly(styrene/divinylbenzene) resins (Applied Biosystems, Inc., Foster City, CA) and tert-butyloxycarbonyl (Boc)-protected amino acids (Applied Biosystems, Inc. or Bachem, Inc., Torrance, CA). Boc-N-methyl-Ala, Boc-Arg(tosyl) or Boc-Arg(mesitylenesulfonyl), Boc-Asp(benzyl), Boc-Cys(4-methoxybenzyl), Boc-Glu(benzyl), Boc-His(benzyloxycarbonyl) or Boc-His(2,4-dinitrophenyl), Boc-D-His(4-toluenesulfonyl), Boc-Lys(chlorobenzyloxycarbonyl), Boc-Met, Boc-Ser(benzyl), Boc-Thr(benzyl), Boc-Trp or Boc-Trp(formyl), and Boc-Tyr(2-bromobenzyloxycarbonyl) were used for the incorporation of the respective amino acid residues. Boc-His(methyl) was incorporated in a manual mode on a 0.02 mmol scale using the N,N-dicyclohexylcarbodiimide/1-hydroxybenzotriazole coupling protocol. All amino acids (except glycine) used herein have the L configuration unless otherwise noted.

Peptides were cleaved from the resin and deprotected in liquid HF/p-cresol/dimethyl sulfide (10:1:0.5) at -5°C for 90 min, or in liquid HF/anisole (9:1, v/v) at 0°C for 90 min. The resins were washed with cold diethyl ether, and the peptides were extracted into 1.0 M acetic acid and lyophilized. Peptides were then purified by RP-HPLC on an Aquapore™ RP-300 C18 silica column (1x10 cm, Applied Biosystems, Inc.), or on an MRPH-Gel™ polystyrene column (1 X 10 cm, The Nest Group, Scarborough, MA) using a 0 - 60% linear gradient of acetonitrile in 0.1% TFA. The purity of each synthetic peptide preparation was confirmed by microbore HPLC on Aquapore™ OD-300 columns of C18 silica (1 X 250 mm, Applied Biosystems, Inc.), quantitative amino acid analysis and sequencing, as described above. Peptides were generally stored in the lyophilized form at 4°C prior to use in the antibacterial assays.

It is understood in the art that there are other suitable peptide synthetic devices or that manual peptide synthesis could be carried out to produce the peptides of the present invention. Automated solid phase peptide synthesis is described, e.g., in Stewart et al. (1984) Solid Phase Peptide Synthesis, Pierce Chemical Company, Rockford, Illinois).

#### Example 2    Antimicrobial Activity Testing

Neisseria gonorrhoeae strain FA 102 and Staphylococcus aureus strain 8325-4 were the test bacteria used in many experiments; these strains have been described previously (Shafer et al. (1986) supra; Shafer and Onunka (1989) J. Gen. Microbiol. 135:825-830). N. gonorrhoeae were passaged on clear typing agar as nonpiliated, transparent variants. For testing, cultures were grown with shaking at 37°C in GC broth containing glucose, iron and sodium bicarbonate supplements. S. aureus was grown at 37°C with shaking in LB broth. At midlogarithmic phase (OD<sub>550</sub> of 0.35) the cultures were diluted in Hanks Balanced Salt Solution (HBSS) (Gibco Laboratories,

Grand Island, New York) (pH 7.5) to give approximately  $10^5$  CFU/ml. In other experiments, P. aeruginosa ATCC 27853, a standard antibiotic tester strain, was used.

5       Peptides were dissolved in HBSS (pH 7.5) and added in various amounts (0 to 100 micrograms) to sterile microtiter wells. After UV sterilization of the wells, 0.1 ml samples of the bacterial were added and the volumes in each well were adjusted with HBSS to 0.2 ml. The bacteria-peptide mixtures were incubated at 37°C for 45-60 min unless otherwise noted.  
10      For N. gonorrhoeae, incubation was carried out under an atmosphere of 5% CO<sub>2</sub>. In other experiments, as noted, 1/100 strength HBSS was used. For at least some strains, the use of 1/100 HBSS resulted in greater sensitivity to the bactericidal activity of the peptides disclosed herein.

15       Viability was determined after incubation by plating 10 and 100 microliter samples on LB agar (S. aureus) or GCB agar (N. gonorrhoeae). All assays were done in duplicate or triplicate, and the results given are the means of three independent experiments. The % survival of the test bacteria  
20      was calculated as  $100 \times (\# \text{ CFU in the presence of peptide}) / (\# \text{ CFU in the absence of peptide})$ ; standard error of the mean for each data point was never greater than 5%.

## SEQUENCE LISTING

## (1) GENERAL INFORMATION:

(i) APPLICANT: Emory University  
University of Georgia  
Research Foundation, Inc.

(ii) TITLE OF INVENTION: Antimicrobial Peptides

(iii) NUMBER OF SEQUENCES: 19

(iv) CORRESPONDENCE ADDRESS:

(A) ADDRESSEE: Greenlee and Winner, P.C.  
(B) STREET: 5370 Manhattan Circle, Suite 201  
(C) CITY: Boulder  
(D) STATE: Colorado  
(E) COUNTRY: USA  
(F) ZIP: 80303

(v) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: Floppy disk  
(B) COMPUTER: IBM PC compatible  
(C) OPERATING SYSTEM: PC-DOS/MS-DOS  
(D) SOFTWARE: PatentIn Release #1.0, Version #1.25

(vi) CURRENT APPLICATION DATA:

(A) APPLICATION NUMBER:  
(B) FILING DATE: 01-OCT-1993  
(C) CLASSIFICATION:

(vii) PRIOR APPLICATION DATA:

(A) APPLICATION NUMBER: US 07/956,848  
(B) FILING DATE: 02-OCT-1992

(viii) ATTORNEY/AGENT INFORMATION:

(A) NAME: Ferber, Donna M.  
(B) REGISTRATION NUMBER: 33,878  
(C) REFERENCE/DOCKET NUMBER: 3-90C PCT

(ix) TELECOMMUNICATION INFORMATION:

(A) TELEPHONE: (303) 499-8080  
(B) TELEFAX: (303) 499-8089

## (2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 21 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

Gly Ile Gly Lys Phe Leu His Ser Ala Lys Lys Phe Lys Ala Phe  
1 5 10 15

5 Val Gly Glu Ile Met Asn  
20

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:  
10 (A) LENGTH: 5 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

15 (v) FRAGMENT TYPE: N-terminal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

Ile Ile Gly Gly Arg  
1 5

(2) INFORMATION FOR SEQ ID NO:3:

20 (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 7 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

25 (ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

30 His Pro Gln Tyr Asn Gln Arg  
1 5

(2) INFORMATION FOR SEQ ID NO:4:

35 (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 20 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

5 Arg Pro Gly Thr Leu Cys Thr Val Ala Gly Trp Gly Arg Val Ser  
1 5 10 15

Met Arg Arg Gly Thr  
20

(2) INFORMATION FOR SEQ ID NO:5:

10 (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 15 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

15 (ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

20 Cys Thr Val Ala Gly Trp Arg Gly Val Ser Met Arg Arg Gly Thr  
1 5 10 15

(2) INFORMATION FOR SEQ ID NO:6:

25 (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 10 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(v) FRAGMENT TYPE: internal

30 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

Trp Gly Arg Val Ser Met Arg Arg Gly Thr  
1 5 10

(2) INFORMATION FOR SEQ ID NO:7:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 20 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

5

- (ii) MOLECULE TYPE: peptide  
 (iii) HYPOTHETICAL: NO  
 (v) FRAGMENT TYPE: internal  
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

10 Arg Arg Glu Asn Thr Gln Gln His Ile Thr Ala Arg Arg Ala Ile  
 1 5 10 15

Arg His Pro Gln Tyr  
 20

(2) INFORMATION FOR SEQ ID NO:8:

- 15 (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 27 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

- 20 (ii) MOLECULE TYPE: peptide  
 (iii) HYPOTHETICAL: NO

(v) FRAGMENT TYPE: C-terminal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

25 Gly Lys Ser Ser Gly Val Pro Pro Glu Val Phe Thr Arg Phe Val  
 1 5 10 15

Ser Ser Phe Leu Pro Trp Ile Arg Thr Thr Met Arg  
 20 25

(2) INFORMATION FOR SEQ ID NO:9:

- 30 (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 20 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

- 35 (iii) HYPOTHETICAL: NO

(v) FRAGMENT TYPE: N-terminal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

Ile Ile Gly Gly Arg Glu Ser Arg Pro His Ser Arg Pro Tyr Met  
1 5 10 15

5 Ala Tyr Leu Gln Ile  
20

(2) INFORMATION FOR SEQ ID NO:10:

(i) SEQUENCE CHARACTERISTICS:

10 (A) LENGTH: 223 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: NO

15 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

Ile Ile Gly Gly Arg Glu Ser Arg Pro His Ser Arg Pro Tyr Met  
1 5 10 15

Ala Tyr Leu Gln Ile Gln Ser Pro Ala Gly Gln Ser Arg Cys Gly  
20 25 30

Gly Phe Leu Val Arg Glu Asp Phe Val Leu Thr Ala Ala His Cys  
35 40 45

25 Trp Gly Ser Asn Ile Asn Val Thr Leu Gly Ala His Asn Ile Asp  
50 55 60

Arg Arg Glu Asn Thr Gln Gln His Ile Thr Ala Arg Arg Ala Ile  
65 70 75

30 Arg His Pro Gln Tyr Asn Gln Arg Thr Ile Gln Asn Asp Ile Met  
80 85 90

Leu Leu Gln Leu Ser Arg Arg Val Arg Arg Asn Arg Asn Val Asn  
95 100 105

35 Pro Val Ala Leu Pro Arg Ala Gln Glu Gly Leu Arg Pro Gly Thr  
110 115 120

Leu Cys Thr Val Ala Gly Trp Gly Arg Val Ser Met Met Arg Gly  
 125 130 135

5 Thr Asp Thr Leu Arg Glu Val Gln Leu Arg Val Gln Arg Asp Arg  
 140 145 150

Gln Cys Leu Arg Ile Phe Gly Ser Tyr Asp Pro Arg Arg Gln Ile  
 155 160 165

10 Cys Val Gly Asp Arg Arg Glu Arg Lys Ala Ala Phe Lys Gly Asp  
 170 175 180

15 Ser Gly Gly Pro Leu Leu Cys Asn Asn Val Ala His Gly Ile Val  
 185 190 195

Ser Tyr Gly Lys Ser Ser Gly Val Pro Pro Glu Val Phe Thr Arg  
 200 205 210

20 Val Ser Ser Phe Leu Pro Trp Ile Arg Thr Thr Met Arg  
 215 220

(2) INFORMATION FOR SEQ ID NO:11:

(i) SEQUENCE CHARACTERISTICS:

25 (A) LENGTH: 20 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(v) FRAGMENT TYPE: internal

30 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

Gln Ser Pro Ala Gly Gln Ser Arg Cys Gly Gly Phe Leu Val Arg  
 1 5 10 15

Glu Asp Phe Val Leu  
 20

35 (2) INFORMATION FOR SEQ ID NO:12:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(v) FRAGMENT TYPE: internal

5 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

Thr Ala Ala His Cys Trp Gly Ser Asn Ile Asn Val Thr Leu Gly  
1 5 10 15

Ala His Asn Ile Gln  
20

10 (2) INFORMATION FOR SEQ ID NO:13:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

15 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

20 His Pro Gln Tyr Asn Gln Arg Thr Ile Gln Asn Asp Ile Met Leu  
1 5 10 15

LeuGln Leu Ser Arg  
20

(2) INFORMATION FOR SEQ ID NO:14:

25 (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

30 (ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

Arg Val Arg Arg Asn Arg Asn Val Asn Pro Val Ala Leu Pro Arg  
1 5 10 15

Ala Gln Glu Gly Leu  
20

(2) INFORMATION FOR SEQ ID NO:15:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

Asp Thr Leu Arg Glu Val Gln Leu Arg Val Gln Arg Asp Arg Gln  
1 5 10 15

Cys Leu Arg Ile Phe  
20

(2) INFORMATION FOR SEQ ID NO:16:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:

Gly Ser Tyr Asp Pro Arg Arg Gln Ile Cys Val Gly Asp Arg Arg  
1 5 10 15

Glu Arg Lys Ala Ala  
20

## (2) INFORMATION FOR SEQ ID NO:17:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 21 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:

Phe Lys Gly Asp Ser Gly Gly Pro Leu Leu Cys Asn Asn Val Ala  
1                      5                      10                      15

His Gly Ile Val Ser Tyr  
20

## (2) INFORMATION FOR SEQ ID NO:18:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 6 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:

His Pro Gln Tyr Asn Gln  
1                      5

## (2) INFORMATION FOR SEQ ID NO:19:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 13 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:

Arg	Pro	Gly	Thr	Leu	Cys	Thr	Val	Ala	Gly	Trp	Gly	Arg
1				5					10			

## WE CLAIM:


1. An oligopeptide having antimicrobial activity, wherein said peptide comprises a sequence selected from the group consisting of RRENTQQHITARRAIRHPQY (SEQ ID NO:7),  
5 GKSSGVPPEVFTRFVSSFLPWIRTTMR (SEQ ID NO:8),  
CTVAGWGRVSMRGGT (SEQ ID NO:5), WGRSMRGGT (SEQ ID NO:6),  
RPGTLCTVAGWGRVSMRRGT (SEQ ID NO:4) and D-enantiomers thereof.
- 10 2. A method of inhibiting growth of a bacterium, said method comprising the step of exposing a bacterium to at least one antimicrobial oligopeptide of claim 1 in an amount effective for reducing viability of said bacterium at least by 90%, wherein the bacterium is sensitive to the antimicrobial activity of at least one of said peptides.
- 15 3. A therapeutic composition suitable for controlling infection by a bacterium, said composition comprising at least one antimicrobial oligopeptide of claim 1 and a pharmacologically acceptable carrier, wherein the bacterium is sensitive to the antimicrobial activity of at  
20 least one of said oligopeptides.
4. A method for controlling infection by a bacterium, said method comprising the step of administering a therapeutically effective amount of the composition of claim 3.
- 25 5. A method of treating gingivitis and/or periodontitis comprising the step of administering a therapeutically effective amount of a therapeutic composition to an affected patient, wherein said therapeutic composition comprises at least one antimicrobial oligopeptide of claim  
30 1, wherein at least one bacterium involved in the gingivitis and/or periodontitis disease process is sensitive to said oligopeptide.

6. The method of claim 5 wherein said step of administering consists of applying said therapeutic composition to the gums of the affected patient.
- 5 7. An oligopeptide having antimicrobial activity, where said oligopeptide comprises an amino acid sequence IIGGRESRPHSRPYMAYLQI (SEQ ID NO:9) or a D-enantiomer thereof.
- 10 8. A method of treating gingivitis and/or periodontitis comprising the step of administering a therapeutically effective amount of a therapeutic composition to an affected patient, wherein said therapeutic composition comprises the oligopeptide of claim 7, and wherein at least one bacterium involved in the gingivitis and/or periodontitis disease process is sensitive to
- 15 IIGGRESRPHSRPYMAYLQI (SEQ ID NO:9).
- 20 9. A therapeutic composition suitable for controlling infection by a bacterium, said composition comprising the antimicrobial oligopeptide of claim 7 and a pharmacologically suitable carrier wherein the bacterium is sensitive to said oligopeptide.

## FIGURE 1

1  
IIGGRESRPHSRPYMAYLQIQSPAGQSRCGGFLVREDFVLTAHCWGSNINVTLGahnid  
61 80 \* 117  
RRENTQOHITARRAIRHPQYNQRTIQNDIMLLQLSRRVRRNRNVNPVALPRAQEGLRPGT  
136 # \*\*\*  
LTVAGWGRVSMMRGTDTLREVQLRVQRDRQCLRIFGSYDPRRQICVGDRRERKAAFKGDS  
### # 223  
GGPLLCNNVAHGIVSYGKSSGVPPEVFTRVSSFLPWIRTMR

FIGURE 2



## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US93/09414

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(5) : A61K 37/02; C07K 7/08, 7/10

US CL : 514/12, 13, 14; 530/324,326

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 514/12, 13, 14; 530/324,326

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	Proc. Natl. Acad. Sci., USA, vol. 86, issued July 1989, Gabay et al, "Antibiotic protein of human polymorphonuclear leukocytes", pages 5610-14, see entire document.	1-9
X	Proc. Natl. Acad. Sci. USA, vol. 84, issued April 1987, Sinha et al, "Primary Structure of Human Neutrophil Elastase", pages 2228-32, see entire document.	1-9
X	Biochemistry, vol 26, No.8, issued 1987, "Molecular Cloning of Human Cathepsin G: Structural Similarity to Mast Cell and Cytotoxic T Lymphocyte Proteinases", pages 2289-93, see entire document.	1-9



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" document defining the general state of the art which is not considered to be part of particular relevance	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E" earlier document published on or after the international filing date	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Z"	document member of the same patent family
"O" document referring to an oral disclosure, use, exhibition or other means		
"P" document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

10 December 1993

Date of mailing of the international search report

21 DEC 1993

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Authorized officer

SANDRA MARSHALL

*S. Kuyza*

100  
100  
100